Lachlan Brown
Stock Analyst at William Blair
(0.62)
# 3,888
Out of 4,876 analysts
10
Total ratings
37.5%
Success rate
-10.71%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $197.25 | +1.39% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $30.88 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $2.60 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $9.22 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $502.63 | +19.37% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $305.20 | +14.68% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $17.43 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $101.46 | -11.30% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $132.87 | +65.58% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $197.25
Upside: +1.39%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $30.88
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.60
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.22
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $502.63
Upside: +19.37%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $305.20
Upside: +14.68%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.43
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $101.46
Upside: -11.30%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $132.87
Upside: +65.58%